Incidence of Premature Discontinuation of Antiplatelet Therapy After Sirolimus-Eluting Stent Implantation

Assessment of Sirolimus-Eluting Coronary Stent Implantation With Aspirin Plus Low Dose Ticlopidine Administration One Year Results From CYPHER Stent Japan Post-Marketing Surveillance Registry (J-PMS)

“…21 These observations suggest that the antiplatelet effect of ticlopidine 200 mg/day was sufficient to prevent thrombotic events in Japan with lower side effect rate of ticlopidine. 22,23 A benefit of this study is the limited case selection bias because no other DESs were available during the study period in Japan. On the contrary, there were several Japanspecific risk factors such as small reference vessel diameter (the average was 2.47 mm), high percent of diabetics (43.3%) and off-label use (68.3%), including 11.2% total occlusion.…”

Early Stent Thrombosis Because of Stent Dislodgement in a Coronary Artery Aneurysm

“…[1][2][3][4][5][6][7] Previous studies report mechanical risk factors of stent thrombosis such as stent underexpansion and vessel dissection, 7,8 and this case report is of an unusual mechanism of stent thrombosis.…”

Silent Very Late Thrombotic Occlusion of Sirolimus-Eluting Stent Confirmed by Directional Coronary Atherectomy

“…[1][2][3][4] Previous clinical studies used relatively restrictive and non-uniform definitions of stent thrombosis 6,7 These definitions uniformly regarded evidence of any myocardial infarction with angiographic confirmation of in-stent thrombus or unexplained death within 30 days after the procedure as stent thrombosis, but varied when myocardial infarction was present without angiographic confirmation of target-vessel involvement. Thus, standardized definitions of stent thrombosis were required and were recently proposed by the newly formed Academic Research Consortium (ARC).…”